Benign breast disease

Author(s):  
P. Jane Clarke ◽  
R. Fiddes

Benign conditions of the breast are very common, but they cause great anxiety, often leading the patient to be concerned that she has breast cancer. Symptoms may include: (1) a mass in the breast, commonly due to fibroadenoma, benign cystic change, or macrocysts; (2) mastalgia; and (3) discharge from the nipple, which may be caused by hyperprolactinaemia, intraduct papilloma, or duct ectasia. Management involves exclusion of malignancy, often by triple assessment of any palpable abnormality (for clinical examination, radiological and pathological assessment, see ...

2020 ◽  
pp. 2406-2408
Author(s):  
Gael M. MacLean

Benign conditions of the breast are very common, but they cause great anxiety, often leading the patient to be concerned that she has breast cancer. Symptoms may include: a mass in the breast, commonly due to fibroadenoma, benign cystic change, or macrocysts; discharge from the nipple, which may be caused by hyperprolactinaemia, intraduct papilloma, or duct ectasia; and mastalgia. Management involves exclusion of malignancy, often by triple assessment of any palpable abnormality (clinical examination, radiological and pathological assessment), followed by reassurance, with appropriate specific treatment if required. Suspicious features such as a hard, rugged lump in the breast should prompt triple assessment to exclude malignancy. Other benign conditions of the male breast are very rare and male breast cancers account for less than 1% of all breast cancers in the United Kingdom.


2018 ◽  
Vol 8 (3) ◽  
pp. 154-161
Author(s):  
Jasmina Gubaljevic ◽  
Nahida Srabović ◽  
Adlija Jevrić-Čaušević ◽  
Adaleta Softić ◽  
Adi Rifatbegović ◽  
...  

Introduction: The aim of this study was to determine the serum levels of malondialdehyde (MDA) in patients with invasive breast cancer in relation to its serum levels in patients with benign breast disease, and to investigate correlation between MDA serum levels with pathohistological prognostic factors (tumor size, lymph node involvement, and histologic grade [HG]), estrogen receptor (ER) status, and with breast cancer patient’s age and menopausal status. Methods: A total of 43 with well-documented invasive breast cancer were included in this study: 27 with positive axillary’s lymph nodes, and 16 with negative axillary’s lymph nodes, and 39 patients with findings of benign breast diseases. MDA determination in serum of breast cancer and benign breast disease patients was performed by the fluorimetric method, immunohistochemical staining was performed for ER, and routine pathohistological examination was conducted for pathohistological factors. Results: MDA serum levels in breast cancer patients were significantly higher than MDA serum levels in benign breast disease patients (p = 0.042). No statistically significant difference between MDA serum levels in breast cancer patients with and without lymph node metastases was found (p = 0.238). No statistically significant correlations between MDA serum levels and tumor size (p = 0.256), HG (p = 0.124), or number of positive lymph nodes (0.113) were found. A statistically significant correlation between serum MDA levels and ages of breast cancer patients with lymph node metastases was found (p = 0.006). Conclusion: Obtained results support the importance of MDA in the carcinogenesis of breast cancer. According to our findings, serum level of MDA could not be a useful prognostic factor in breast cancer.


Cancer ◽  
2006 ◽  
Vol 107 (6) ◽  
pp. 1240-1247 ◽  
Author(s):  
Laura C. Collins ◽  
Heather J. Baer ◽  
Rulla M. Tamimi ◽  
James L. Connolly ◽  
Graham A. Colditz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document